Abstract:Background: Physiologically based pharmacokinetic (PBPK) modeling and simulating may be a powerful tool in predicting drug behaviors in specific populations. It is a mathematical model that relates the pharmacokinetic (PK) profile of a compound with human anatomical characteristics, physiological characteristics, and biochemical parameters. Predictions using PBPK models offer a promising way to guide drug development and can be used to optimize clinical dosing regimens. However, PK data of new drugs in the pediatric population are too limited to guide clinical therapy, which may lead to frequent adverse events or insufficient efficacy for pediatric patients, particularly in neonates and infants.Objective: The objective of this study was to establish a virtual Chinese pediatric population based on the physiological parameters of Chinese children that could be utilized in PBPK models.Methods: A Chinese pediatric PBPK model was developed in Simcyp Simulator by collecting published Chinese pediatric physiological and anthropometric data to use as system parameters. This pediatric population model was then evaluated in the Chinese pediatric population by predicting the pharmacokinetic characteristics of four probe drugs: theophylline (major CYP1A2 substrate), fentanyl (major CYP3A4 substrate), vancomycin, and ceftazidime (renal-eliminated).Results: The predicted maximum concentration (Cmax), area under the curve of concentration-time (AUC), and clearance (CL) for theophylline (CYP1A2 metabolism pathway) and fentanyl (CYP3A4 metabolism pathway) were within two folds of the observed data. For drugs mainly eliminated by renal clearance (vancomycin and ceftazidime) in the Chinese pediatric population, the ratio of prediction to observation for major PK parameters was within a 2-fold error range.Conclusion: The model is a supplement to the previous Chinese population PBPK model. We anticipate the model to be a better representative of the pediatric Chinese population for drugs PK, offering greater clinical precision for medication given to the pediatric population, ultimately advancing clinical development of pediatric drugs. We can refine this model further by collecting more physiological parameters of Chinese children.

Population Pharmacokinetics of Omeprazole in Healthy Volunteers of Different Nationalities in China by NONMEM

Population Pharmacokinetics of Zolpidem Tartrate Tablets in Healthy Volunteers of Five Different Nationalities in China

Characterization of Omeprazole Pharmacokinetics in Chinese Extensive and Poor Metabolizers

Establish the Population Pharmacokinetics Model of Azithromycin in Chinese Healthy Volunteers

Evaluation of the Relationship Between Polymorphisms in CYP2C19 and the Single‐dose Pharmacokinetics of Omeprazole in Healthy Chinese Volunteers: A Multicenter Study

Development of a particle swarm optimization-backpropagation artificial neural network model and effects of age and gender on pharmacokinetics study of omeprazole enteric-coated tablets in Chinese population

Population Pharmacokinetics of Ambroxol Hydrochloride in Chinese Healthy Male Subjects

Population Pharmacokinetics of Tinidazole in Five Different Ethnic Populations of China

Population pharmacokinetics of citalopram by NONMEM

Development of a Population Pharmacokinetic Model of Olanzapine for Chinese Health Volunteers and Patients with Schizophrenia.

Population Pharmacokinetics of Doxapram in Five Different Chinese Ethnic Groups

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Population pharmacokinetics of combined ethinylestradiol/gestodene transdermal contraceptive tablets and patches in Chinese healthy volunteers

Preliminary study on population pharmacokinetic model of metformin sustainedrelease tablets in healthy subjects

Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis

Development of a Physiologically Based Pharmacokinetic (PBPK) Population Model for Chinese Elderly Subjects

Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms

Systematic Review of Influence of CYP2C19 Genetic Polymorphism on Pharmacokinetics of Omeprazole

Population Pharmacokinetics of Modafinil Acid and Estimation of the Metabolic Conversion of Modafinil into Modafinil Acid in 5 Major Ethnic Groups of China

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways